In the News: US Biotech Restrictions Against China; China Regulates Non-Compete Clauses; and Hong Kong Stablecoins

U.S. pharma raises alarm over Trump’s proposed measures against Chinese drugs; China clarifies the type of employees to be bound by non-compete clauses; and Some stablecoin issuers complain that Hong Kong’s regime is too stringent.

By Brian Chan

In the News: US Biotech Restrictions Against China; China Regulates Non-Compete Clauses; and Hong Kong Stablecoins

US Proposes Crackdown of Chinese-Invented Treatments

The U.S. is considering tough restrictions on medicines and treatments invented in China, a move strongly opposed by U.S. pharmaceutical companies.

If enacted, American patients could lose access to promising treatments made in China, according to the New York Times.

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

✓ A database of 3000+ essential documents, including key PRC laws translated into English
✓ Newsletters with business-critical and sector-specific updates
✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)